Amoy Diagnostics Co., Ltd. (300685.SZ) Bundle
Who is buying into Amoy Diagnostics Co., Ltd. (300685.SZ) and why the market is paying attention: a striking 41% of shares sit with individual investors, while 26% are held by institutional players and 32% by private companies, creating a mix of retail enthusiasm, institutional validation and strategic corporate stakes-with Qianzhan Investment (Hong Kong) Co., Ltd. alone controlling a 22% block and the top nine shareholders together owning 51% of the company; investors are also reacting to hard financial traction, as market capitalization has surged by 422.10% since August 2, 2017 (from 1.60 billion CNY to 8.34 billion CNY) and revenue topped over 1 billion CNY in 2023 with a year‑on‑year rise of 23.91%, while strategic moves like the Haihe Biopharma collaboration on U.S. companion diagnostics add further context-read on to unpack who the key players are, what their stakes signal for governance and growth prospects, and which investor motives are driving buying activity.
Amoy Diagnostics Co., Ltd. (300685.SZ) - Who Invests in Amoy Diagnostics Co., Ltd. (300685.SZ) and Why?
- Individual investors: 41% - strong retail interest reflecting confidence in growth potential and biotech sector exposure.
- Institutional investors: 26% - moderate institutional conviction, likely driven by stable revenue growth and scalable diagnostics products.
- Private companies: 32% - strategic, vested-owner positions suggesting partnerships, supply-chain or IP-related alignment.
| Metric | Value | Notes |
|---|---|---|
| Top 9 shareholders (collective) | 51% | Concentrated ownership; influences corporate strategy |
| Qianzhan Investment (Hong Kong) Co., Ltd. | 22% | Largest single shareholder - strategic anchor investor |
| Individual investors | 41% | Retail-driven liquidity and sentiment-sensitive flows |
| Institutional investors | 26% | Includes mutual funds, trusts, possible healthcare-focused funds |
| Private companies | 32% | Likely trade partners, industry investors, or related parties |
| Market capitalization (2 Aug 2017) | 1.60 billion CNY | Base for growth calculation |
| Market capitalization (latest) | 8.34 billion CNY | +422.10% since 2017-08-02 |
| Revenue (2023) | >1.00 billion CNY | YoY growth: 23.91% |
- Why individuals invest: perceived high-growth story, retail momentum, accessible share liquidity, and positive topline trends (2023 revenue >1 billion CNY; +23.91% YoY).
- Why institutions invest: improving financials and scalable product offerings; diversification into diagnostics amid healthcare demand.
- Why private companies invest: strategic alignment, potential for supply-chain integration, IP access, or long-term partnership value-underscored by concentrated ownership (top nine = 51%).
Amoy Diagnostics Co., Ltd. (300685.SZ) Institutional Ownership and Major Shareholders of Amoy Diagnostics Co., Ltd.
Amoy Diagnostics Co., Ltd. (300685.SZ) shows a concentrated ownership base with several large strategic and financial holders driving votes and capital allocation. The ownership mix and recent operating growth underpin investor interest and explain part of the pronounced re-rating in market capitalization since 2017.- Largest shareholder: Qianzhan Investment (Hong Kong) Co., Ltd. - 22.0% ownership, a controlling strategic stake that aligns company performance with investor objectives.
- Significant PE/partnership holders: Xiamen Yixiang Investment Partnership Enterprise (LP) - 5.1%; Xiamen Keying Investment Partnership Enterprise (LP) - 5.1%.
- Top nine shareholders combined: 51.0% of total shares, indicating a concentrated top‑holder block.
- Institutional ownership: 26.0% of free float held by institutional investors, reflecting moderate institutional confidence and room for further institutional inflows.
| Holder | Type | Ownership (%) |
|---|---|---|
| Qianzhan Investment (Hong Kong) Co., Ltd. | Strategic/Investment | 22.0 |
| Xiamen Yixiang Investment Partnership (LP) | Private equity/Partnership | 5.1 |
| Xiamen Keying Investment Partnership (LP) | Private equity/Partnership | 5.1 |
| Other top 6 shareholders (aggregate) | Mixed (insiders, funds) | 18.8 |
| Top 9 shareholders (total) | Aggregate | 51.0 |
| Institutional investors (aggregate) | Mutual funds, asset managers | 26.0 |
- Market capitalization growth: increased by 422.10% since August 2, 2017 - from CNY 1.60 billion to CNY 8.34 billion - demonstrating significant re‑rating and investor confidence.
- Revenue momentum: 2023 revenue exceeded CNY 1.0 billion, representing a 23.91% year‑on‑year increase, strengthening the growth narrative for biotech/diagnostics investors.
- Ownership concentration: with over half the company in the hands of the top nine holders, strategic/long‑term investors can materially influence governance and strategic direction.
Amoy Diagnostics Co., Ltd. (300685.SZ) Key Investors and Their Impact on Amoy Diagnostics Co., Ltd. (300685.SZ)
- Largest shareholder: Qianzhan Investment (Hong Kong) Co., Ltd. - 22.0% stake, potential decisive influence on board composition, strategic direction, M&A and capital allocation.
- Significant paired investors: Xiamen Yixiang Investment Partnership (LP) - 5.1% and Xiamen Keying Investment Partnership (LP) - 5.1%; combined stake 10.2%, able to coordinate with other major holders to influence corporate actions.
- Top nine shareholders combined ownership: 51.0% - indicates concentrated control and the potential for coordinated decision-making among major holders.
- Institutional ownership: 26.0% - a moderate institutional presence that provides professional oversight but leaves control largely with strategic/long-term shareholders.
| Item | Value / Detail | Implication |
|---|---|---|
| Qianzhan Investment (HK) Co., Ltd. | 22.0% | Largest single-block controller; strong board influence |
| Xiamen Yixiang Investment Partnership (LP) | 5.1% | Significant strategic shareholder |
| Xiamen Keying Investment Partnership (LP) | 5.1% | Paired influence with Yixiang; combined 10.2% |
| Top nine shareholders (aggregate) | 51.0% | Concentrated ownership; potential for block voting |
| Institutional investors (aggregate) | 26.0% | Moderate institutional confidence and oversight |
| Market capitalization (2017-08-02) | 1.60 billion CNY | Baseline for growth comparison |
| Market capitalization (current) | 8.34 billion CNY | +422.10% since 2017-08-02 |
| Revenue (2023) | >1.00 billion CNY | YoY +23.91%; growth attracts growth-oriented investors |
- Investor types attracting Amoy Diagnostics: strategic corporate holders (e.g., regional investment firms), growth-oriented funds betting on diagnostics expansion, and selective institutional investors providing validation and liquidity.
- Impacts on governance and strategy:
- With 22% held by a single entity and 51% concentrated among top nine, coordinated decisions on dividends, R&D spend, and listing-related moves are more feasible.
- Institutional 26% stake tempers speculative volatility and supports governance practices, but ultimate control remains with strategic shareholders.
- Market-performance drivers highlighted by ownership and financials:
- Market cap surge (+422.10%) signals investor confidence tied to operational scale-up and revenue momentum.
- 2023 revenue >1.00 billion CNY with 23.91% YoY growth is a concrete attractor for growth-focused funds and sector specialists.
Amoy Diagnostics Co., Ltd. (300685.SZ) Market Impact and Investor Sentiment
Amoy Diagnostics Co., Ltd. (300685.SZ) has seen a dramatic valuation expansion and growing operational scale that together shape investor sentiment and market impact. Since August 2, 2017, market capitalization climbed 422.10% from 1.60 billion CNY to 8.34 billion CNY, signaling strong investor confidence and perceived growth potential. Revenue surpassed 1.0 billion CNY in 2023 - a 23.91% year‑on‑year increase - reinforcing the growth narrative for equity and fixed‑income investors focused on biotech exposure.- Market capitalization growth (2017-present): +422.10% (1.60B CNY → 8.34B CNY)
- 2023 revenue: >1.0B CNY; YoY growth: 23.91%
- Institutional ownership: 26% - moderate institutional confidence
- Individual ownership: 41% - substantial retail participation
- Top-nine shareholders ownership: 51% - concentrated ownership with potential governance influence
- Key strategic partnership: collaboration with Haihe Biopharma to co-develop companion diagnostics for the U.S. market
| Metric | Value |
|---|---|
| Market Capitalization (Aug 2, 2017) | 1.60 billion CNY |
| Market Capitalization (current) | 8.34 billion CNY |
| % Change (2017 → current) | +422.10% |
| Revenue (2023) | >1.0 billion CNY |
| Revenue YoY (2023) | +23.91% |
| Institutional Ownership | 26% |
| Individual (Retail) Ownership | 41% |
| Top‑9 Shareholders Ownership | 51% |
| Notable Strategic Partnership | Haihe Biopharma - co‑development of U.S. companion diagnostics |
Amoy Diagnostics Co., Ltd. (300685.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.